Antabio

Antabio is a privately held, clinical-stage biopharmaceutical company dedicated to developing novel and highly differentiated antibacterial treatments targeting drug-resistant infections caused by WHO and CDC critical priority pathogens. Guided by scientific excellence and a clear mission, Antabio’s mission is to deliver life-saving therapies that combat antimicrobial resistance (AMR) and help preserve the effectiveness of antibiotics for future generations. Antabio’s lead program, MEM-ANT3310, is a next-generation β-lactam/β-lactamase inhibitor (BL/BLI) combination currently in Phase 1 clinical development. Designed to treat severe hospital infections caused by multidrug-resistant Gram-negative bacteria, MEM-ANT3310 represents a major step forward in addressing one of the most urgent public health challenges of our time.